Document is current
Any future updates will be listed below
-
Authors
Gephine, Sarah
Mucci, Patrick
Bielmann, Mathieu
Martin, Mickael
Bouyer, Laurent
Saey, Didier
Maltais, François
-
Funding
Funding for this research was provided by:
Fonds de Recherche du Québec–Santé
Le Fond sur les maladies respiratoires J.-D.-Bégin – P.-H.-Lavoie, Université Laval
GSK COPD Research Chair at Université Laval
- License Information
-
More Information
Article History
Received: 3 July 2021
Accepted: 13 December 2021
First Online: 17 January 2022
Competing interests
: FM reports grants from GlaxoSmithKline, AstraZeneca, Sanofi, Novartis, Boehringer Ingelheim, and Grifols, personal fees from GlaxoSmithKline, Boehringer Ingelheim, Grifols, and Novartis, and reports having a financial participation in Oxynov, a company which is developing an oxygen delivery system outside the submitted work. The funders played no role in the design, conduct or reporting of this study. SG, PM, MB, MM, LB and DS have no conflict of interest to disclose.
